IVF/ART/Infertility

FRIDAY, NOVEMBER 22

08:30-10:00 AMH vs AFC…AND THE WINNER IS……?
Hall A
Capsule What is the role of AMH in the diagnosis and treatment of infertility?
Chairpersons Scott Nelson, UK
Nick Macklon, UK
08:30-09:15 Debate: Is AMH a good predictor for success in IVF cycles?
Pro: Antonio La Marca, Italy
Con: Joop Laven, Netherlands
09:15-10:00 Debate: Are we really misinforming young women on their reproductive potential by using AMH and AFC testing?
Yes: Edgardo Somigliana, Italy
No: Antonio La Marca, Italy
10:00-10:20 COFFEE BREAK AND POSTER VIEWING
EXIBITION AREA
10:20-11:50 PCOS/PCO
Hall A
Capsule PCOS is considered the most common endocrine disorder in reproductive age. However, the prevalence (6.5-17.8%), as well as the long-term risks, vary widely with the diagnostic tests and criteria. Should we change the criteria?
Chairpersons Roger A. Lobo, USA
Zion Ben Rafael
, Israel
10:20-11:05 Debate: Androgens are the villain in PCOS
Con: Joop Laven, Netherlands
Pro: Jerome Strauss, USA
11:05-11:50 Debate: We must screen PCOS cases for the presence of the metabolic syndrome
Pro: Bart Fauser, Netherlands
Con: Phillippe Bouchard, France
11:50-12:10 BREAK
EXIBITION AREA
12:10-13:40 INDUSTRY SUPPORTED SESSION
Hall A
13:40-14:30 LUNCH BREAK AND POSTER VIEWING
EXIBITION AREA
14:30-16:30 STIMULATION, OOCYTES AND EMBRYOS
Hall A
Capsule Stimulation, the first step in IVF, has never had consensus..
Chairpersons Victor Gomel, Canada
Scott Nelson, UK
14:30-15:00 Debate: Ovarian stimulation More or Less?
Less is more: Geeta Nargund UK
No! New twists in ovarian stimulation: More is better: Dominique de Ziegler, France
15:00-15:20 GnRH agonists and IVF: The end …. or not?
Joelle Belaisch Allart, France
15:20-15:40 The numbers of small (2-5 and 6-9 mmm) follicles are inversely correlated in both normal women and in PCOS: What is the missing link?
Sophie Catteau-Jonard, France
15:40-16:30 COGI SPECIAL COUNTERCURRENT SYMPOSIA
Capsule The next stage in improving the result, is understanding what’s wrong with what we’re doing
15:40-16:05 RCTs may not be the answer to all outstanding questions in IVF
Bart Fauser, Netherlands
16:05-16:30 Repeated implantation failure:  An iatrogenic phenomenon which leads to two unnecessary activities
Zion Ben Rafael, Israel
16:30-16:50 COFFEE BREAK AND POSTER VIEWING
EXIBITION AREA
16:50-18:20 ADENOMYOSIS AND ENDOMETRIOSIS
Hall A
Capsule The concept that uterine adenomyosis and pelvic endometriosis as well as endometriotic lesions at distant sites of the body share a common pathophysiology with endometriosis was promoted almost a decade ago. What is the current thinking?
Chairpersons Marie-Madeline Dolmans, Belgium
Philippe Descamps, France
Aleksandar Stefanović, Serbia
16:50-17:10 Adenomyosis and deep endometriosis: Two linked diseases?
Jacques Donnez, Belgium
17:10-17:45 Debate: The endometrioma and the ovarian reserve: The challenge of the surgeon
To operate first: Herve Fernandez, France
ART before operation: Edgardo Somigliana, Italy
17:45-18:20 Debate: Deep-endometriosis should be operated prior to ART
Pro for surgery first: Olivier Donnez, Belgium
Cons for IVF first (against surgery): Pietro Santulli, France

SATURDAY, NOVEMBER 23

08:30-10:00 PGT-A
Hall A
Capsule Is PGS useful or harmful?
Chairpersons Simon Fishel, UK
Gerald Schatten, USA
08:30-08:55 PGT-A for Advances maternal age and repeated abortions, useful or harmful?
Nathan Treff, USA
08:55-09:15 RCT of PGT for aneuploidy by microarray of polar body in advance maternal age. Any advantage? The Esteem Study
Luca Ginaroli, Italy
09:15-09:35 Euploidy in donor eggs varies greatly between centers
TBA
09:35-10:00 PGD/PGT-A without embryo biopsy, is this the answer?
Samir Hamamah, France
10:00-10:20 COFFEE BREAK AND POSTER VIEWING
EXIBITION AREA
10:20-11:50 INDUTRY SUPPORTED SESSION
Hall A
11:50-12:10 BREAK
EXIBITION AREA
12:10-13:40 QUESTIONS AND ANSWERS
Hall A
Chairpersons Zion Ben Rafael¸ Israel
Rene Frydman, France
Bart Fauser, Netherlands
Discussants Edgardo Somigliana, Italy
Nick Macklon, UK
Joop Laven, Netherlands
Samir Hamamah, France
Simon Fishel, UK
Laura Rienzi¸ Italy
  • LH or hCG: Which is more important for ovarian stimulation
  • In which selected patient populations is PGT-A proven beneficial
  • ERA test- who can benefit
  • Freeze all embryos strategies in IVF for all
  • Duo stim? Why bother?
  • Embryo selection with highest implantation potential, tell me how?
  • Natural and Natural/mild cycles, are they the same? Are we misleading each other?
  • Is Machine Learning beginning to improve IVF outcomes; what can we expect in the  future
  • What is the best measure of IVF outcome from clinical, patients, healthcare system?
  • Is SET possible for all? l if not what is the percentage of SET should we strive for? Should it be age dependent?
13:40-14:30 LUNCH BREAK AND POSTER VIEWING
EXIBITION AREA
14:30-16:30 HITECH IVF:  ARTIFICIAL GAMETE AND EMBRYOS
Hall A
Capsule Current capability promise more ethical questions.
Chairpersons Dominique De Ziegler, France
14:30-14:50 Conception versus manufacturing:  ART Prospects with artificial gametes and assembled embryos
Gerald Schatten, USA
14:50-15:15 Self-organization of the human embryo in the absence of maternal tissues
Matteo Mole, UK
15:15-15:40 Artificial ovary
Marie Madeleine Dolmans, Belgium
15:40-16:00 Expanding PGT to polygenic risk
Nathan Treff, USA
16:00-16:30 Special countercurrent lecture:
Are we overusing IVF
Fulco van der Veen, Netherlands
16:30-16:50 COFFEE BREAK AND POSTER VIEWING
EXIBITION AREA
16:50-18:20 FREEZE ALL
Hall A
Capsule Freeze only strategy became popular before any study to its efficacy appeared. Now that RCTs failed to proof of its usefulness to all, it’s time to discuss the overall advantages and disadvantages
Chairpersons Amelia Rodríguez-Aranda, Spain
Rene Frydman, France
16:50-17:20 Debate: Freeze only strategy for all?
Con: Ben Mol, Australia
Pro: Anja Pinborg, Denmark
17:20-17:40 Comparing fresh and frozen embryo transfers in IVF; Cost effectiveness analysis
Ben Mol, Australia
17:40-18:20 Debate: Should we measure progesterone on the day of a frozen embryo transfer?
No : Annalisa Racca, Belgium
Yes: Elena Labarta, Spain

FRIDAY, NOVEMBER 22

08:30-10:00 SCREENING OF THE MAN FOR INFERTILITY
Hall B
Capsule Have we neglected the treatment of male infertility? Can better screening improve the overall results?
Chairpersons Christopher Barratt,UK
Christopher De Jonge, USA
Giuseppe Tritto, France
08:30-08:35 Introduction
Christopher Barratt, UK
08:35-09:00 Screening of the man for infertility; Why its necessary (canary in the coal mine)
Michael Eisenberg, USA
09:00-09:25 The Male Reproductive Health initiative
Christopher De Jonge, USA
09:25-09:50 Use of Social Media platforms to inform the public about male reproductive health issues
Allan Pacey, UK
09:50-10:00 Discussion
10:00-10:20 COFFEE BREAK AND POSTER VIEWING
EXIBITION AREA
10:20-11:50 BLASTOCYSTS
Hall B
Capsule Single euploid, morphologically intact blastocyst seems like the holy grail of IVF. So why we are still debating?
Chairpersons Anja Pinborg, Denmark
Ben Mol, Australia
10:20-11:05 Debate: Blastocyst-stage embryo transfer for all
Yes: Samir Hamamah, France
No: Amelia Rodríguez-Aranda, Spain
11:05-11:30 Chromosomal mosaicism in human blastocysts: The ultimate challenge of preimplantation genetic testing?
Mina Popovic, Belgium
11:30-11:50 Prevalence of XXY karyotypes in human blastocysts: Multicenter data from 7549 trophectoderm biopsies obtained during preimplantation genetic testing cycles in IVF
Laura Rienzi, Italy
11:50-12:10 BREAK
EXIBITION AREA
12:10-13:40 LABORATORY WORK
Hall B
Capsule Basic issues in Lab work are still controversial
Chairperson Samir Hamamah, France
12:10-12:30 IVF and the lab: Which culture medium to use
Aafke van Montfoort, Netherlands
12:30-13:15 Debate: Still room for embryo morphological evaluation?
Yes: in favor Luca Ginaroli, Italy
No: against Marine Poulain, France
13:15-13:40 The secret lives of human embryos exposed through time-lapse.  An analysis of over 300 SET cycles
Diana Stein, Israel
13:40-14:30 LUNCH BREAK AND POSTER VIEWING
EXIBITION AREA
14:30-16:30 IMPLANTATION MODELS
Hall B
Capsule IVF failure is mainly due to embryonal or endometrial reasons?
Chairpersons Nick Macklon,UK
Simon Fishel, UK
14:30-14:50 Complex endometrial organoids to model embryo implantation
Emma Lucas, UK
14:50-15:15 Organoids from healthy and diseased endometrium as innovative research tools in reproductive biology
Hugo Vankelecom, Belgium
15:15-15:40 Implantation Clinic: Hope or hype?
Nick Macklon, UK
15:40-16:30 SPECIAL COGI COUNTERCURRENT LECTURES
15:40-16:05 Can IVF influence human evolution?
Hans Ivar Hanevik, Norway
16:05-16:30 Endometrial receptivity testing: Can the most reliable test stand up?
Samuel Dos Santos Ribeiro, Belgium
16:30-16:50 COFFEE BREAK AND POSTER VIEWING
EXIBITION AREA
16:50-18:20 ADD-ON TREATMENTS
Hall B
Capsule Add-on treatments: The best solution to keep patients from quitting the program?
Chairpersons Laura Rienzi, Italy
Scott Nelson, UK
16:50-17:35 Debate: Standard IVF vs Add-on IVF – What if the patient is willing to pay for add-ons?
Con: Joyce Harper, UK
Pro: Simon Fishel, UK
17:35-18:00 ICSI does not increase the cumulative live birth rate in non-male factor infertility
Elizabeth A. Sullivan, Australia
18:00-18:20 Is there a relationship between the time to ICSI and the reproductive outcomes?
Amelia Rodríguez-Aranda, Spain

SATURDAY, NOVEMBER 23

08:30-10:00 FERTILITY PRESERVATION
Hall B
Capsule With so many methods of fertility preservation, do they all offer similar probabilities?
Chairpersons Jacques Donnez, Belgium
Michael Grynberg, France
08:30-08:50 How many eggs do we need for preserving fertility?
Nathalie Sermondade, France
08:50-09:15 Oocytes or ovarian cortex cryopreservation for fertility preservation
Jean-Philippe Wolf, France
09:15-09:35 The place of IVM for fertility preservation
Michael Grynberg, France
09:35-10:00 Ovarian tissue cryopreservation and transplantation: Still experimental?
Marie-Madeline Dolmans, Belgium
10:00-10:20 COFFEE BREAK AND POSTER VIEWING
EXIBITION AREA
10:20-11:50 DIAGNOSIS OF INFERTILITY
Hall B
Capsule Why Should we keep doing HSG? Uterine transplantation, what kind of results can be expected?
Chairperson Rene Frydman, France
10:20-10:50 Uterine transplantation – The French experience
Jean Marc Ayoubi, France
10:50-11:35 Debate: Hysterosalpingogram how?
Traditional oil-based HSG exploiting its therapeutic advantage: Ben Mol, Australia
Ecosy is a good alternative: Marc Even, France
11:35-11:50 Biomarkers of ovarian response
Scott Nelson, UK
11:50-12:10 BREAK
EXIBITION AREA
12:10-13:40 GO TO HALL A – QUESTIONS AND ANSWERS SESSION
Hall B
13:40-14:30 LUNCH BREAK AND POSTER VIEWING
EXIBITION AREA
14:30-16:30 WHAT’S NEW IN POI RESEARCH – I
Hall B
Capsule Can POI patients have any chance for fertility?
Chairpersons Lisa Webber, UK
Nicholas Panay, UK
14:30-14:50 Genetics of menopause
Joop Laven, Netherlands
14:50-15:20 Genetics of POI. Novel links with DNA repair/cancer genes
Micheline Misrahi, France
15:20-15:40 Fertility and management of Turner syndrome
Sophie Christin-Maitre, France
15:40-16:00 Stem cells in and out the ovaries: Promises for POI
Gabriel Livera, France
16:00-16:30 Countercurrent lecture
Vaginal Lactobacilli: key to successful human reproduction and future antibiotic resistant therapy
Gary Ventolini, USA
16:30-16:50 COFFEE BREAK AND POSTER VIEWING
EXIBITION AREA
16:50-18:20 WHAT’S NEW IN POI RESEARCH – PART II
Hall B
Chairpersons Roger A. Lobo, USA
Micheline Misrahi, France
16:50-17:10 Can we reliably predict POI using AMH?
Bart Fauser, Netherlands
17:10-17:35 Regulation of physiological reproductive lifespan and female fertility
Grant Montgomery, Australia
17:35-17:55 Developing new guidelines from a POI registry
Nicholas Panay, UK
17:55-18:20 The long-term health risks of POI
Lisa Webber, UK